| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -1.1 | -2.5 |
| EPS (diluted, $ a share) | $-0.05 | $-0.58 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: SNGX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Soligenix, Inc.: key numbers
- Share price
- $0.2882Close, Nov 16
- Market cap
- $6.73M
- Shares outstanding
- 23.37MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Soligenix, Inc.
All →Soligenix Shareholder Meeting
Soligenix held its 2026 Annual Meeting of Stockholders where shareholders elected five directors and approved several key proposals. Major outcomes included the ratification of an increase in authorized common shares from 75 million to 125 million and the approval of a discretionary reverse stock split at a ratio between 1-for-2 and 1-for-20.